Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before TAVI

Study Overview
=================
Brief Summary
-----------------
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. The loss of muscle mass in chronic heart failure patients is a prognostic factor for sarcopenia. The purpose was to identify in these patients signs of sarcopenia for a better management.

Detailed Description
-----------------
Age-related muscle loss, termed sarcopenia, affects 10% of elderly subjects aged 60-70 years and more than 30% above the age of 80. The concept of sarcopenia has been supported by the recent findings of muscular atrophy which was related to the decrease of protein synthesis because of the anabolic resistance, affecting the muscular fibers type II. In fact, sarcopenia could be a consequence of chronic disease and not only an issue in the elderly people. The diagnosis is assessed by the weak muscle mass and the muscle strength and function. A description of these muscle parameters has been described in a study of 200 patients with NYHA class II-III and showed that 19,5 % have a decrease in muscle mass. They also showed that these patients have a lower functional ability. These findings prompted us to investigate the prevalence of sarcopenia in chronic heart failure subjects for a better management of these patients.

Official Title
-----------------
Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before Transcatheter Aortic Valve Implantation

Conditions
-----------------
Sarcopenia, Chronic Heart Failure

Intervention / Treatment
-----------------
* Diagnostic Test: Assessment of sarcopenia prevalence


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major patients (>18 years) Men or women Hospitalized in pre- trans aortic valvular implantation assessment in the cardiology department of the university hospital centre of Clermont-Ferrand or Patients with chronic heart failure in charge in the hospital of Clermont-Ferrand or convalescence in the pneumocardiological clinic of Durtol Exclusion Criteria: Patient not affiliated to social security Inability to understand the information consent letter Not having signed informed consent Has a mental or legal incapacitation and is unable to provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Heart failure patients<br>The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. | Diagnostic Test: Assessment of sarcopenia prevalence<br>* Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test<br>|
| Experimental: TAVI patients<br>The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. | Diagnostic Test: Assessment of sarcopenia prevalence<br>* Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioimpedance analysis data | Fat-free mass and body fat mass will be combined to report BMI in Kg/m2 | at day 1 | 
| Short physical performance battery | Balance test, 4-min walking test, 5 times getting-up test | at day 1 | 
| Handgrip test |  | at day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood draw for serum creatinine in umol/L | Measure of inflammation | at day 1 | 
| CRP in mg/L | Measure of inflammation | at day 1 | 
| platelets in Giga/L | Measure of inflammation | at day 1 | 
| complete blood count CBC (white blood cells in Giga/L and red blood cells in Tera/L) | Measure of inflammation | at day 1 | 
| urea in mmol/L | Measure of inflammation | at day 1 | 
| albumin in g/L | Measure of inflammation | at day 1 | 
| NT-ProBNP in ng/L | Measure of inflammation | at day 1 | 
| Electrocardiogram | Parameter which may interfere with sarcopenia | at day 1 | 
| Trans-thoracic echography | Parameter which may interfere with sarcopenia | at day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sarcopenia, Heart failure (HF), The trans aortic valvular implantation (TAVI)